Ruth Mangupli1, Liliya Rostomyan2, Emilie Castermans3, Jean-Hubert Caberg3, Paul Camperos4, Jaime Krivoy4, Elvia Cuauro4, Vincent Bours3, Adrian F Daly2, Albert Beckers5. 1. Section of Neuroendocrinology, Department of Neurosurgery, Hospital Universitario de Caracas, Caracas, Venezuela. nenhuc@gmail.com. 2. Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, 4000, Liège, Belgium. 3. Department of Human Genetics, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, 4000, Liège, Belgium. 4. Section of Neuroendocrinology, Department of Neurosurgery, Hospital Universitario de Caracas, Caracas, Venezuela. 5. Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, 4000, Liège, Belgium. albert.beckers@chu.ulg.ac.be.
Abstract
INTRODUCTION: Pituitary gigantism is a rare condition caused by growth hormone secreting hypersecretion, usually by a pituitary tumor. Acromegaly and gigantism cases that have a genetic cause are challenging to treat, due to large tumor size and poor responses to some medical therapies (e.g. AIP mutation affected cases and those with X-linked acrogigantism syndrome). MATERIALS AND METHODS: We performed a retrospective study to identify gigantism cases among 160 somatotropinoma patients treated between 1985 and 2015 at the University Hospital of Caracas, Venezuela. We studied clinical details at diagnosis, hormonal responses to therapy and undertook targeted genetic testing. Among the 160 cases, eight patients (six males; 75 %) were diagnosed with pituitary gigantism and underwent genetic analysis that included array comparative genome hybridization for Xq26.3 duplications. RESULTS: All patients had GH secreting pituitary macroadenomas that were difficult to control with conventional treatment options, such as surgery or primary somatostatin receptor ligand (SRL) therapy. Combined therapy (long-acting SRL and pegvisomant) as primary treatment or after pituitary surgery and radiotherapy permitted the normalization of IGF-1 levels and clinical improvement. Novel AIP mutations were the found in three patients. None of the patients had Xq26.3 microduplications. CONCLUSIONS: Treatment of pituitary gigantism is frequently challenging; delayed control increases the harmful effects of GH excess, such as, excessive stature and symptom burden, so early diagnosis and effective treatment are particularly important in these cases.
INTRODUCTION:Pituitary gigantism is a rare condition caused by growth hormone secreting hypersecretion, usually by a pituitary tumor. Acromegaly and gigantism cases that have a genetic cause are challenging to treat, due to large tumor size and poor responses to some medical therapies (e.g. AIP mutation affected cases and those with X-linked acrogigantism syndrome). MATERIALS AND METHODS: We performed a retrospective study to identify gigantism cases among 160 somatotropinomapatients treated between 1985 and 2015 at the University Hospital of Caracas, Venezuela. We studied clinical details at diagnosis, hormonal responses to therapy and undertook targeted genetic testing. Among the 160 cases, eight patients (six males; 75 %) were diagnosed with pituitary gigantism and underwent genetic analysis that included array comparative genome hybridization for Xq26.3 duplications. RESULTS: All patients had GH secreting pituitary macroadenomas that were difficult to control with conventional treatment options, such as surgery or primary somatostatin receptor ligand (SRL) therapy. Combined therapy (long-acting SRL and pegvisomant) as primary treatment or after pituitary surgery and radiotherapy permitted the normalization of IGF-1 levels and clinical improvement. Novel AIP mutations were the found in three patients. None of the patients had Xq26.3 microduplications. CONCLUSIONS: Treatment of pituitary gigantism is frequently challenging; delayed control increases the harmful effects of GH excess, such as, excessive stature and symptom burden, so early diagnosis and effective treatment are particularly important in these cases.
Authors: H G Maheshwari; T R Prezant; V Herman-Bonert; H Shahinian; K Kovacs; S Melmed Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: S Bergamaschi; C L Ronchi; C Giavoli; E Ferrante; E Verrua; D I Ferrari; A Lania; R Rusconi; A Spada; P Beck-Peccoz Journal: Horm Res Paediatr Date: 2010-01-15 Impact factor: 2.852
Authors: Albert Beckers; Maya Beth Lodish; Giampaolo Trivellin; Liliya Rostomyan; Misu Lee; Fabio R Faucz; Bo Yuan; Catherine S Choong; Jean-Hubert Caberg; Elisa Verrua; Luciana Ansaneli Naves; Tim D Cheetham; Jacques Young; Philippe A Lysy; Patrick Petrossians; Andrew Cotterill; Nalini Samir Shah; Daniel Metzger; Emilie Castermans; Maria Rosaria Ambrosio; Chiara Villa; Natalia Strebkova; Nadia Mazerkina; Stéphan Gaillard; Gustavo Barcelos Barra; Luis Augusto Casulari; Sebastian J Neggers; Roberto Salvatori; Marie-Lise Jaffrain-Rea; Margaret Zacharin; Beatriz Lecumberri Santamaria; Sabina Zacharieva; Ee Mun Lim; Giovanna Mantovani; Maria Chaira Zatelli; Michael T Collins; Jean-François Bonneville; Martha Quezado; Prashant Chittiboina; Edward H Oldfield; Vincent Bours; Pengfei Liu; Wouter W de Herder; Natalia Pellegata; James R Lupski; Adrian F Daly; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2015-02-24 Impact factor: 5.678
Authors: Giampaolo Trivellin; Adrian F Daly; Fabio R Faucz; Bo Yuan; Liliya Rostomyan; Darwin O Larco; Marie Helene Schernthaner-Reiter; Eva Szarek; Letícia F Leal; Jean-Hubert Caberg; Emilie Castermans; Chiara Villa; Aggeliki Dimopoulos; Prashant Chittiboina; Paraskevi Xekouki; Nalini Shah; Daniel Metzger; Philippe A Lysy; Emanuele Ferrante; Natalia Strebkova; Nadia Mazerkina; Maria Chiara Zatelli; Maya Lodish; Anelia Horvath; Rodrigo Bertollo de Alexandre; Allison D Manning; Isaac Levy; Margaret F Keil; Maria de la Luz Sierra; Leonor Palmeira; Wouter Coppieters; Michel Georges; Luciana A Naves; Mauricette Jamar; Vincent Bours; T John Wu; Catherine S Choong; Jerome Bertherat; Philippe Chanson; Peter Kamenický; William E Farrell; Anne Barlier; Martha Quezado; Ivana Bjelobaba; Stanko S Stojilkovic; Jurgen Wess; Stefano Costanzi; Pengfei Liu; James R Lupski; Albert Beckers; Constantine A Stratakis Journal: N Engl J Med Date: 2014-12-03 Impact factor: 91.245
Authors: Ellen Schoof; Helmuth G Dörr; Wieland Kiess; Dieter K Lüdecke; Eduard Freitag; Volker Zindel; Wolfgang Rascher; Jörg Dötsch Journal: Horm Res Date: 2004-01-23
Authors: Adrian F Daly; Bo Yuan; Frederic Fina; Jean-Hubert Caberg; Giampaolo Trivellin; Liliya Rostomyan; Wouter W de Herder; Luciana A Naves; Daniel Metzger; Thomas Cuny; Wolfgang Rabl; Nalini Shah; Marie-Lise Jaffrain-Rea; Maria Chiara Zatelli; Fabio R Faucz; Emilie Castermans; Isabelle Nanni-Metellus; Maya Lodish; Ammar Muhammad; Leonor Palmeira; Iulia Potorac; Giovanna Mantovani; Sebastian J Neggers; Marc Klein; Anne Barlier; Pengfei Liu; L'Houcine Ouafik; Vincent Bours; James R Lupski; Constantine A Stratakis; Albert Beckers Journal: Endocr Relat Cancer Date: 2016-03-02 Impact factor: 5.678
Authors: S J C M M Neggers; M O van Aken; W W de Herder; R A Feelders; J A M J L Janssen; X Badia; S M Webb; A J van der Lely Journal: J Clin Endocrinol Metab Date: 2008-07-22 Impact factor: 5.958
Authors: Ericka B Trarbach; Giampaolo Trivellin; Isabella P P Grande; Felipe H G Duarte; Alexander A L Jorge; Felipe Barjud Pereira do Nascimento; Heraldo M Garmes; Marcia Nery; Berenice B Mendonca; Constantine A Stratakis; Marcello D Bronstein; Raquel S Jallad Journal: Pituitary Date: 2020-11-06 Impact factor: 4.107
Authors: Medard F M van den Broek; Bernadette P M van Nesselrooij; Annemarie A Verrijn Stuart; Rachel S van Leeuwaarde; Gerlof D Valk Journal: Front Endocrinol (Lausanne) Date: 2019-12-10 Impact factor: 5.555